B-type natriuretic peptide (BNP) is a hormone secreted by the ventricles under hemodynamic stress and congestive failure.
INTRODUCTION
A hemodynamically significant patent ductus arteriosus (hsPDA) is present in approximately 60% of preterm neonates during the first week of life. 1 An hsPDA causes a left to right shunt, which worsens lung compliance, produces cardiac failure and is associated with an increased risk of intraventricular hemorrhage, chronic lung disease and mortality. [2] [3] [4] Early treatment of hsPDA reduces symptoms, the need for surgical ligation and the duration of ventilatory support and hospitalization in premature neonates. 5, 6 It is essential, therefore, to diagnose an hsPDA promptly and treat it appropriately.
Currently, hsPDA is suggested by a combination of clinical signs and chest radiographic findings and the diagnosis is confirmed by an echocardiogram. The common clinical signs associated with an hsPDA include a murmur, bounding pulses, wide pulse pressures and cardiomegaly; however, these findings are not uniformly present. [7] [8] [9] [10] Although the echocardiogram is the gold standard for the diagnosis of an hsPDA, expense and technical requirements preclude its use as a screening tool.
B-type natriuretic peptide (BNP) is a neurocardiac hormone secreted from the ventricles in response to ventricular volume and pressure overload and increased wall tension. 11 Plasma BNP levels have emerged as valuable diagnostic and prognostic markers of various heart conditions in adults, including left ventricular enlargement and dysfunction and right ventricular hypertrophy and volume overload. 12 Plasma BNP levels differentiate dyspnea of pulmonary origin from congestive heart failure (CHF), correlate with the severity of CHF and are independent predictors of adverse outcome in patients after myocardial infarction. [13] [14] [15] In pediatric patients, BNP levels are increased in patients with hemodynamically significant ventricular septal defects, correlating with volume of shunt and left ventricular end diastolic volume. 16 Two previous studies have shown that plasma BNP is elevated in the presence of patent ductus arteriosus (PDA), but the diagnostic utility of the assay as a screening test has not been evaluated. 17, 18 The objective of the present study, therefore, was to evaluate plasma BNP as a screening test for the presence of hsPDA in preterm neonates. The specific aims were to determine whether plasma BNP can be used to diagnose an hsPDA where clinical suspicion exists, whether it can differentiate an hsPDA from an insignificant PDA, and whether a change in BNP level predicts the successful treatment of hsPDA. 
MATERIALS AND METHODS

This
Selection Criteria
Preterm neonates with birth weights between 500 and 1500 g were eligible for enrollment in the first month of life when an echocardiogram was ordered by the NICU staff for a clinical suspicion of PDA. Infants with congenital cardiac defects, shortening fraction <28%, a need for vasopressor support (dopamine and/or dobutamine >5 mg/kg/min), chromosomal defects, multiple noncardiac malformations, documented sepsis, persistent pulmonary hypertension of the newborn, necrotizing enterocolitis, renal failure (blood urea nitrogen >30 mg/dl or serum creatinine >2.0 mg/dl) or Apgar score <3 at 10 minutes were excluded, since these conditions may be associated with increased plasma BNP levels. 16, 19, 20 Clinical Data Clinical data including birth weight, gestational age, gender, use of antenatal steroids and surfactant and fluid intake in the 24 hours preceding enrollment were collected from the medical records.
Echocardiography
The initial echocardiogram at the time of enrollment was performed at the request of the treating neonatologist for clinical suspicion of PDA. Patients who did not have a PDA or did not receive any treatment had a repeat echocardiogram 48 to 72 hours after the first study as part of the protocol. Newborns who were treated with indomethacin or surgical ligation had a repeat echocardiogram 48 to 72 hours after the completion of treatment. A third echocardiogram was performed in some patients when a PDA was again clinically suspected after the first course of indomethacin treatment. A patient could have a maximum of three echocardiograms as a part of the research protocol.
Echocardiograms were performed using a Phillips Sonos 5500. M mode was used to calculate the shortening fraction and to measure left ventricular internal diameter in diastole (left ventricle (LV)). A two-dimensional parasternal long axis view was obtained for assessment of the diameter of the left atrium (LA) in systole and aortic root diameter (AO). Ratios of LA/AO and LV/AO were calculated off-line from these diameters. A two-dimentional ductal view with color Doppler was performed to assess the ductal shunting and the minimum diameter of the PDA. A single cardiologist (MP), blinded to clinical and plasma BNP data interpreted all echocardiograms.
Criteria for hsPDA. The definition of a hemodynamically significant PDA was based on previously established criteria and was defined by the presence of at least two of the following three parameters: 21 1. LA/AO ratio of more than 1.4:1 2. LV/AO ratio of more than 2.1:1 3. Narrowest ductal diameter >1.5 mm Blood Sampling for BNP Levels Blood samples (0.5 ml) were collected in K-EDTA microtubes within 3 hours of each echocardiogram and were spun immediately at 3500 rpm for 10 minutes. Platelet-free plasma was stored at À201C until BNP analysis of all collected samples. The BNP assay was performed using the Triage BNP kit (Biosite Diagnostic, San Diego, CA), a fluorescence immunoassay, which has a measurable range of 5 to 1300 pg/ml. This bedside test has previously been shown to be a reliable method to rapidly measure BNP in patients with suspected CHF. 14 
Statistical Analysis
The statistical analyses were performed using SPSS (version 11.5) software for windows. Data were expressed as mean±SD for continuous variables and as a number (percentage) for categorical variables. Echocardiographic data were used to divide patients into two groups, based on the presence or absence of an hsPDA. These two groups were compared for continuous variables using the t-test for independent samples and analysis of variance. To compare the categorical variables between the two groups, Pearson's w test or Fisher's exact test was used as appropriate. Box and whisker plots of BNP levels were used to show the distribution in the subgroups based on presence of hsPDA. The sensitivity, specificity, positive and negative predictive value, and negative and positive likelihood ratio were calculated using 2 way contingency table analysis. The 95% confidence intervals for each of these parameters were obtained by the ''constant w 2 boundaries method''. 22 Receiver operator characteristics (ROC) curves were constructed for different plasma BNP cutoff values to determine the optimal sensitivity and specificity and area under the curve. Statistical significance was set as p<0.05. All hypotheses were two-tailed.
RESULTS
Baseline Characteristics
A total of 29 premature neonates were enrolled in the study. These included 13 (45%) male and 16 (55%) female neonates. The birth weight (mean±SD) was 873.5±247 g, and the gestational age was 26±2 weeks. The age at enrollment into the study varied from 2 to 28 days, with a median of 7 days and mode of 2 days. In total, 15 (52%) infants were born via vaginal delivery and the remainder by cesarean section. In total, 25 (87%) infants had received antenatal steroids and 24 (85%) required surfactant administration. At the time of enrollment, 25 (87%) subjects were on ventilatory support.
Echocardiographic and Clinical Data
The 29 enrolled infants underwent a total of 67 echocardiograms (29 initial echocardiograms, 28 repeat echocardiograms and a third echocardiogram in 10 infants). One infant underwent only a single echocardiogram before death from causes unrelated to the PDA.
On the initial echo, 14 of 29 neonates had hsPDA while 15 had either non-hsPDA (n ¼ 6) or no PDA (n ¼ 9). Four patients continued to have an hsPDA on the echo following treatment and one had persistence of hsPDA on the third echo. Newborns with hsPDA had significantly greater left atrial size (1.06±0.2 vs 0.79±0. 19) , left ventricular size (1.42±0.21 vs 1.17±0. 19 ) and ductal size (0.26±0.07 vs 0.05±0.07) compared to the group without hsPDA. There was no difference in the aortic root size between the groups.
The two subgroups of patients with and without hsPDA did not differ in age at enrollment, birth weight, gestational age, gender or volume of fluid administered in the 24 hours preceding enrollment (Table 1) .
Plasma BNP Data
Plasma BNP levels in neonates with hsPDA (n ¼ 14) was significantly higher than in neonates with either no PDA or nonhsPDA (n ¼ 15) (508.5±618.2 vs 59.5±69.9 pg/ml, p<0.005). The mean (±SD) BNP levels in the group with hsPDA (n ¼ 14), non-hsPDA (n ¼ 6) and no PDA (n ¼ 9) were 508.5±618.2, 96.2±98.6 and 35.1±27.9 pg/ml, respectively. As shown in Figure 1 , the BNP levels in the group with hsPDA were significantly higher than the group with either no PDA or a non-hsPDA (p ¼ 0.02 and 0.05, respectively for each pairwise comparison). Table 2 depicts the sensitivities, specificities, negative and positive predictive values and positive and negative likelihood ratios along with the 95% confidence intervals of plasma BNP in diagnosing hsPDA using various cutoff values. ROC curves were generated for various BNP levels in the diagnosis of hsPDA. The area under the curve was maximum (0.91, 95% CI 0.83 to 0.99) at a cutoff value of 70 pg/ml. At this cutoff, it was possible to diagnose hsPDA with a sensitivity of 92.9% and specificity of 73.3%. The positive predictive value at this cutoff was 76.5% while the negative predictive value was 92%. The likelihood ratio for positive test was 3.5 and for a negative test was 0.09.
Value of BNP in Diagnosing hsPDA
Effect of PDA Closure on Plasma BNP Levels
Of the 14 patients with hsPDA on the initial echocardiogram, 12 patients were treated successfully. One infant died before closure and the other continued to have an hsPDA despite two courses of indomethacin. In the group with successful PDA closure, plasma BNP dropped significantly within 48 to 72 hours from a mean (±SD) of 404.94±159.3 to 25.09±4.1 pg/ml (p ¼ 0.03). Plasma BNP remained elevated above 70 pg/dl in the patient who had a persistent hsPDA despite treatment.
Effect of Age on Plasma BNP
In the 29 neonates as a whole, plasma BNP levels (mean±SD) were similar before and after 7 days of age (370.04.±563.60 (n ¼ 17) vs 143.45±309.30 (n ¼ 12), p ¼ 0.2). Similarly, when the hsPDA group was compared before and after 7 days of life, plasma BNP did not differ (690.8±704.78 (n ¼ 8) vs 265.53±417.22 (n ¼ 6) p ¼ 0.2). However, there was a trend towards higher plasma BNP levels in neonates without hsPDA before 7 days of life (84.9±79.5 pg/ml, n ¼ 9) than after (21.36±25.2 pg/ml, n ¼ 6 and p ¼ 0.08). Regardless of age, a plasma BNP cutoff value of 70 pg/dl had excellent sensitivity and negative predictive value (100 and 84% sensitivity, 100 and 84% negative predictive value before and after 7 days of age).
DISCUSSION
An hsPDA is common in preterm infants in the neonatal intensive care unit and is associated with significant morbidity. [2] [3] [4] The condition is difficult to diagnose reliably based on clinical symptoms and signs. 8, 9 An echocardiogram, though currently the gold standard, involves considerable expense and may not be available immediately, especially in community hospitals. A rapid screening test for hsPDA would therefore, greatly add to the care of preterm neonates. BNP levels are increasingly useful in diagnosis, management and assessing prognosis of heart failure in adults and children. In infants with large left to right atrial and ventricular shunts, BNP levels correlate with the degree of shunting and decrease to control levels when the shunt is eliminated. 16, 23 A significant left to right shunt from an hsPDA causes volume overload of the left side of the heart and consequent secretion of BNP, which we observed in preterm infants with hsPDA but not with an insignificant PDA.
Two previous studies on plasma BNP in preterm neonates demonstrated BNP elevation in the presence of a PDA. 17, 18 Our study defined a cutoff value at which plasma BNP performs as a sensitive marker for diagnosing hsPDA. In our study, the echocardiogram and plasma BNP levels were performed within 3 hours of each other and at the time of clinical suspicion of hsPDA rather than a prespecified age as was performed in the cited studies.
Our results suggest that plasma BNP can be used in the initial screening of preterm neonates suspected clinically to have hsPDA. Since a normal BNP (<70 pg/ml) has an excellent negative predictive value of 92%, an echocardiogram in this case may be avoided. This approach may reduce the expense of patient care contributed by an echocardiogram. An hsPDA is significantly more likely in presence of an elevated BNP (likelihood ratio of 3.5 at a BNP cutoff >70 pg/ml). Since the prevalence of hsPDA is 60% in preterm neonates with a birth weight <1500 g, this gives a plasma BNP >70 pg/ml a post test probability of 80%. 1, 24 Therefore, if BNP is elevated, an echocardiogram is indicated for differentiation of hsPDA from other conditions that can elevate BNP, including structural cardiac anomalies and left ventricular dysfunction. Furthermore, this study demonstrates that BNP allows the discrimination of a hsPDA from an insignificant ductus detected by an echocardiogram, in which case unnecessary courses of potentially toxic medications may be avoided. Plasma BNP levels decrease promptly following successful closure of hsPDA (by medical or surgical means) to the range found in preterm infants without an hsPDA, making it useful for monitoring efficacy of treatment. Concern about a recurrent or persistent hsPDA after 25 However, plasma BNP is a nonspecific marker of cardiac disease and may be elevated in other conditions associated with LV enlargement or dysfunction, arrhythmias and renal failure. 26, 27 Although plasma BNP tended to be higher in the first week of life compared to the second week in infants without an hsPDA, the age-related changes did not affect the sensitivity of plasma BNP in the diagnosis of hsPDA. Establishing the normal developmental changes in plasma BNP would require a larger sample size.
CONCLUSIONS
BNP is significantly higher in preterm neonates with a hemodynamically significant PDA than in those with an insignificant PDA or no PDA. Plasma BNP at a cutoff value of 70 pg/ml is a very sensitive and specific biomarker for the diagnosis of hsPDA. The return of BNP to normal after treatment of hsPDA is indicative of clinical success.
